🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 19 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 01/03/2002 | 21,89 | 22,47 | 21,55 | 22,00 | +0,87% | 4,20% | 570.400 |
| 28/02/2002 | 21,91 | 22,22 | 21,40 | 21,81 | -0,95% | 3,74% | 1.143.000 |
| 27/02/2002 | 22,24 | 22,53 | 21,96 | 22,02 | +0,18% | 2,56% | 757.000 |
| 26/02/2002 | 20,68 | 22,20 | 20,46 | 21,98 | +6,13% | 8,41% | 1.336.600 |
| 25/02/2002 | 21,32 | 21,32 | 19,76 | 20,71 | -3,04% | 7,32% | 935.500 |
| 22/02/2002 | 21,15 | 21,73 | 20,56 | 21,36 | +0,90% | 5,53% | 637.400 |
| 21/02/2002 | 22,45 | 22,45 | 21,11 | 21,17 | -5,24% | 5,97% | 562.700 |
| 20/02/2002 | 22,02 | 22,95 | 21,30 | 22,34 | +1,96% | 7,49% | 1.012.000 |
| 19/02/2002 | 22,20 | 22,31 | 21,56 | 21,91 | -3,40% | 3,38% | 1.051.300 |
| 15/02/2002 | 23,20 | 23,30 | 21,75 | 22,68 | -1,73% | 6,68% | 848.400 |
| 14/02/2002 | 23,09 | 24,36 | 22,70 | 23,08 | -1,41% | 7,19% | 862.000 |
| 13/02/2002 | 23,98 | 23,99 | 22,60 | 23,41 | -1,14% | 5,80% | 727.400 |
| 12/02/2002 | 21,70 | 24,18 | 21,29 | 23,68 | +8,82% | 13,32% | 1.445.800 |
| 11/02/2002 | 20,65 | 21,88 | 20,48 | 21,76 | +5,12% | 6,78% | 838.400 |
| 08/02/2002 | 18,91 | 20,80 | 18,90 | 20,70 | +9,29% | 10,05% | 984.700 |
| 07/02/2002 | 18,44 | 19,22 | 17,78 | 18,94 | +2,43% | 7,81% | 1.386.800 |
| 06/02/2002 | 18,95 | 19,13 | 18,01 | 18,49 | -1,65% | 5,91% | 1.204.600 |
| 05/02/2002 | 19,75 | 19,93 | 18,62 | 18,80 | -5,10% | 6,63% | 761.800 |
| 04/02/2002 | 20,01 | 20,10 | 19,16 | 19,81 | -2,41% | 4,70% | 1.164.100 |
| 01/02/2002 | 19,68 | 20,60 | 19,68 | 20,30 | +2,84% | 4,67% | 782.400 |
| 31/01/2002 | 20,10 | 20,41 | 19,60 | 19,74 | -1,60% | 4,03% | 449.700 |
| 30/01/2002 | 20,53 | 20,54 | 19,37 | 20,06 | -1,91% | 5,70% | 841.900 |
| 29/01/2002 | 20,58 | 21,38 | 19,90 | 20,45 | -1,26% | 7,19% | 517.100 |
| 28/01/2002 | 21,45 | 21,60 | 20,52 | 20,71 | -3,31% | 5,03% | 386.500 |
| 25/01/2002 | 20,80 | 21,60 | 20,61 | 21,42 | +2,10% | 4,76% | 391.400 |
| 24/01/2002 | 21,55 | 21,60 | 20,79 | 20,98 | -1,73% | 3,76% | 355.000 |
| 23/01/2002 | 21,03 | 22,00 | 20,48 | 21,35 | +2,25% | 7,23% | 494.100 |
| 22/01/2002 | 20,98 | 21,48 | 20,48 | 20,88 | -0,24% | 4,77% | 613.400 |
| 18/01/2002 | 21,65 | 22,38 | 20,85 | 20,93 | -3,55% | 7,07% | 693.200 |
| 17/01/2002 | 21,78 | 21,88 | 20,70 | 21,70 | +1,21% | 5,42% | 843.000 |